CHEK2 and neoplasm: Notably, by selectively inhibiting checkpoint kinase activity, CHK2 inhibitors significantly enhance the sensitivity of tumor cells to DNA‐damaging drugs, effectively overcome chemoresistance, and provide a highly promising therapeutic strategy for improving patient prognosis [76].